These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18328354)

  • 1. Cinacalcet for the treatment of primary hyperparathyroidism.
    Sajid-Crockett S; Singer FR; Hershman JM
    Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
    Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
    Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.
    Peacock M; Bilezikian JP; Klassen PS; Guo MD; Turner SA; Shoback D
    J Clin Endocrinol Metab; 2005 Jan; 90(1):135-41. PubMed ID: 15522938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
    Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
    Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
    Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
    Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride.
    Sloand JA; Shelly MA
    Am J Kidney Dis; 2006 Nov; 48(5):832-7. PubMed ID: 17060004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
    Paschoalin RP; Torregrosa JV; Sánchez-Escuredo A; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Nov; 44(9):2588-9. PubMed ID: 23146463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
    Shoback DM; Bilezikian JP; Turner SA; McCary LC; Guo MD; Peacock M
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5644-9. PubMed ID: 14671147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
    Serra AL; Schwarz AA; Wick FH; Marti HP; Wüthrich RP
    Nephrol Dial Transplant; 2005 Jul; 20(7):1315-9. PubMed ID: 15941845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
    de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
    Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.
    Falchetti A; Cilotti A; Vaggelli L; Masi L; Amedei A; Cioppi F; Tonelli F; Brandi ML
    Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):351-7. PubMed ID: 18414463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
    Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
    Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.
    Fukagawa M; Yumita S; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S;
    Nephrol Dial Transplant; 2008 Jan; 23(1):328-35. PubMed ID: 17717030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
    Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation.
    Gómez Marqués G; Obrador Mulet A; Vilar Gimeno A; Pascual Felip MJ; Alarcón Zurita A; Molina Guasch M; Uriol Rivera M; Munar Vila MA; Losada González P
    Transplant Proc; 2009; 41(6):2139-43. PubMed ID: 19715856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
    Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
    Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
    Norman J; Lopez J; Politz D
    Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.
    Silverberg SJ; Rubin MR; Faiman C; Peacock M; Shoback DM; Smallridge RC; Schwanauer LE; Olson KA; Klassen P; Bilezikian JP
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3803-8. PubMed ID: 17666472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.